BACE1 and Alzheimer disease: However, all previously discovered natural and synthetic BACE1 inhibitors have failed clinical trials as therapeutic candidates for AD mainly due to adverse effects, such as ocular toxicity15 and poor BBB penetration with low brain:plasma concentration ratios16.